Search

Displaying results 8421 - 8430 of 9881 in total
  1. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile.

  2. Drug

    Alisertib

    go.drugbank.com/drugs/DB05220
    Investigational

    Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.

  3. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been app...

    Categories: UGT2B7 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  4. Drug

    Ronacaleret

    go.drugbank.com/drugs/DB05255
    Investigational

    Ronacaleret is a calcium-sensing receptor antagonist.

  5. Drug

    Brivaracetam

    go.drugbank.com/drugs/DB05541
    ApprovedInvestigational

    Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].

  6. Drug

    Gantacurium

    go.drugbank.com/drugs/DB05710
    Investigational

    Gantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.

  7. Drug

    Dovitinib

    go.drugbank.com/drugs/DB05928
    Investigational

    Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with...

  8. Drug

    Bradanicline

    go.drugbank.com/drugs/DB06090
    Investigational

    Bradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders. … Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7).

  9. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. … SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.

    Synonyms: 1-(3-chlorophenyl)-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}urea
  10. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. … [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.